Sarepta Therapeutics Inc at Cowen Health Care Conference (Virtual) Transcript

Mar 09, 2022 / 07:10PM GMT
Ritu Subhalaksmi Baral - Cowen and Company, LLC, Research Division - MD & Senior Biotechnology Analyst

Good afternoon, everyone. Welcome to the home stretch Day 3 of Cowen's 2022 Healthcare Conference. I'm senior analyst Ritu Baral, covering analyst on Sarepta. And thanks for joining the Sarepta fireside chat. With us today is CEO, Doug Ingram. Hi, Doug, thanks for joining us. So let's get started.

Questions and Answers:

Ritu Subhalaksmi Baral - Cowen and Company, LLC, Research Division - MD & Senior Biotechnology Analyst

Literally, every single Sarepta question that I've had since your earnings call has been on your guidance, long-term guidance that you gave unexpectedly, unexpectedly on the call last week, where you promised potential breakeven by 2024, $4 billion in revenue guidance 2025 and potentially $10 billion by the end of the decade. You and I spoke about this briefly, but why now? Did the plan come together internally? Do you get more clarity from FDA on something? Is this the start of corporate strategy, et cetera?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot